Recruiting
Phase 2
Phase 3

Sponsor:

Taiho Oncology, Inc.

Code:

NCT04256317

Conditions

Myelodysplastic Syndromes

Acute Myeloid Leukemia

Myelodysplastic Syndrome/Neoplasm

Chronic Myelomonocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Azacitidine

ASTX030 (cedazuridine + azacitidine)

Azacitidine

ASTX030 (cedazuridine + azacitidine)

Cedazuridine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Taiho Oncology, Inc. on 2025-05-02.